Federal Trade Commission sues WPATH over transgender care claims
The Federal Trade Commission (FTC) and four U.S. states have initiated a lawsuit against the World Professional Association for Transgender Health (WPATH), alleging misleading practices in the organization’s guidelines for transgender care for minors, reports BritPanorama.
The complaint asserts that WPATH has made deceptive claims about the safety and efficacy of transgender medical treatments for minors, while allegedly profiting from these claims. The states involved in the lawsuit include Alaska, Iowa, Nebraska, and Texas.
FTC Chairman Andrew Ferguson stated on X, “Parents have a right to make informed decisions about their children’s health. The FTC will not allow parents and children to be deceived by medical organizations and providers who are prioritizing profit over children’s health and safety.”
Additionally, the lawsuit claims that WPATH failed to disclose potential side effects associated with certain pediatric medical transition services, including hormone treatments, leading doctors to disseminate “false, misleading or unsubstantiated statements” about safety and efficacy found in WPATH’s guidelines.
The FTC’s complaint seeks to prevent WPATH from further violations of the FTC Act and other statutes, while also calling for civil penalties and financial awards for the plaintiff states.
WPATH has responded by asserting that its guidelines promote individualized patient care rather than a “one size fits all” approach. The organization emphasized that “transgender and gender-diverse patients deserve the highest level of care from their medical professionals,” advocating for open dialogue and clear communication in healthcare.
Lawrence Gostin, an international public health expert at Georgetown University, described the lawsuit as a “significant expansion” of the FTC’s prior healthcare enforcement practices, noting that it challenges a medical association’s standards of care using consumer protection law. He highlighted that the FTC rarely examines the scientific foundations of clinical medical guidelines.
Gostin expressed concern about the political implications of the lawsuit, stating, “The FTC would be highly unlikely to second-guess clinical guidelines in areas that do not align with its political agenda.” Leaders at the Department of Health and Human Services have praised the FTC’s actions, citing an HHS review that critically analyzed WPATH standards, although this report faced backlash from major medical associations and those involved in the treatment of transgender youth.
Standards for transgender care among youth, widely implemented across the U.S., advocate for collaborative planning among healthcare experts and families, balancing supportive talk therapy with potential medical interventions like puberty blockers or hormone treatments. However, many adolescents experiencing gender dysphoria opt not to pursue medical options such as medications or surgeries.
For over 50 years, WPATH has established commonly accepted medical standards grounded in scientific evidence, expert consensus, and patient-centered values. The organization does not provide direct medical care but has become a pivotal source for guidelines in transgender health.
The lawsuit follows previous investigations into WPATH, which had previously sought to block a similar probe, claiming it violated its First Amendment rights. A federal judge had ruled temporarily in favor of WPATH, halting the investigation.
WPATH asserted its position in response to the lawsuit, maintaining that the FTC’s actions constitute a retaliatory measure against the organization. In its statement, WPATH anticipated a similar ruling against the FTC’s ongoing efforts to undermine gender-affirming care.
Statistics indicate that fewer than 1 in 1,000 adolescents in the U.S. received medication related to transgender care, while recent studies have shown approximately 1,200 patients underwent surgeries related to transgender care over the past year.
Amid these developments, discussions continue within the medical community regarding age-appropriate guidelines for surgeries. The largest professional organization for plastic surgeons recently recommended delaying surgeries for transgender minors until the age of 19, while many other major medical associations advocate for a case-by-case approach, highlighting the need for caution in such decisions.
